Veterinary Neurodegenerative Disease Diagnostics Market Size, Share & Trends Analysis Report By Animal Type (Companion, Livestock), By Product, By Indication, By Diagnostic Tests, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Veterinary Neurodegenerative Disease Diagnostics Market Summary

Furthermore, the expansion of veterinary services in emerging markets is significantly driving the growth of the veterinary neurodegenerative medicine industry, fueled by rising pet ownership, increasing awareness of animal health, and growing investments in veterinary infrastructure. Countries in Asia-Pacific, Latin America, and parts of Africa are witnessing a surge in the establishment of veterinary clinics, mobile care units, and diagnostic labs equipped with advanced neurological tools like MRI and CT.

Moreover, according to an article published by Mad Barn, in April 2025, Arabian horses are genetically predisposed to several autosomal recessive diseases. One of them is Cerebellar Abiotrophy (CA), a neurodegenerative disorder that affects balance and motor coordination due to the degeneration of neurons in the cerebellum. This condition arises when an affected foal inherits two defective copies of a gene from carrier parents. Their breeding history significantly influences the prevalence of such diseases in Arabian horses. Historically, small numbers of Arabian horses were exported from the Middle East to other parts of the world to establish new breeding populations. These limited founder populations underwent genetic bottlenecks, leading to reduced genetic diversity. With fewer genetic variations in the gene pool, the likelihood of mating between carriers of the same recessive mutation increased, raising the incidence of heritable neurological conditions like CA.

This genetic vulnerability is a key factor driving growth in the veterinary neurodegenerative medicine industry. The increased risk of inherited disorders among Arabian horses elevates the demand for specialized veterinary services, including advanced genetic testing, neurological diagnostics, and long-term disease management. Breeders and owners now rely more on DNA screening to identify carriers and prevent the spread of these conditions through selective breeding. At the same time, veterinary professionals require neuroimaging tools, disease-specific therapies, and supportive treatments to manage affected animals. Given the high economic and emotional value of Arabian horses, owners are more likely to invest in cutting-edge healthcare solutions, further stimulating innovation and spending in the equine neurology segment of the veterinary market.

Furthermore, the uptake of pet insurance significantly contributes to the market growth, as it reduces the financial burden on pet owners, making advanced diagnostics and treatments more accessible. Neurological disorders in animals, such as degenerative myelopathy, cerebellar abiotrophy, and intervertebral disc disease, often require costly interventions, including MRI/CT scans, long-term medication, specialist consultations, and sometimes surgery. Without insurance, the high cost may deter pet owners from pursuing comprehensive care. However, with the rising adoption of pet insurance, more owners can afford these treatments, leading to increased demand for neurodiagnostic tools, specialized neurology services, and long-term therapeutics.

Market Concentration & Characteristic

The veterinary neurodegenerative disease diagnostics industry exhibits a high market concentration, and the pace of the market growth is accelerating. One of the key factors fueling the market growth is rapid technological advancements. For instance, according to an article published by National Library of Medicine, in recent years, veterinary medicine has seen major advancements in the development and accessibility of advanced diagnostic imaging technologies, which were once limited to specialized veterinary centers or research institutions. Today, tools like computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine (such as PET and SPECT scans), and hybrid imaging modalities have become increasingly common in veterinary practices. These technologies provide detailed, high-resolution images of animals’ internal structures, allowing for more accurate diagnosis and better understanding of complex conditions, particularly neurodegenerative and musculoskeletal diseases.

The degree of innovation is high, driven by advances in diagnostic technologies, therapeutic development, and digital health integration. Cutting-edge imaging tools like high-field MRI and hybrid PET/MRI systems are enhancing early and precise detection of neurological disorders in animals. At the same time, breakthroughs in molecular diagnostics and genetic testing enable the identification of hereditary neurodegenerative diseases with greater accuracy.

The market experiences a moderate level of mergers and acquisitions, driven by increasing demand for advanced diagnostic solutions and the strategic efforts of key players to strengthen their technological expertise and broaden their global presence. For instance, in August 2023, the German diagnostics company Synlab, active in both human and animal health sectors, agreed to sell its animal health diagnostics division to Mars Inc. This transaction enables Synlab to focus on its core businesses, while SYNLAB VET is anticipated to expand and develop further under Mars' ownership.

Regulations have a significant impact on the veterinary neurodegenerative disease diagnostics industry, shaping product development, approval processes, and market access. Regulatory bodies such as the U.S. Department of Agriculture (USDA), the European Medicines Agency (EMA), and national veterinary authorities enforce strict guidelines to ensure the safety, accuracy, and reliability of diagnostic tests. These regulations mandate thorough validation and quality control procedures, which can increase the time and cost associated with bringing new diagnostics to market. However, they also enhance consumer and veterinarian confidence by ensuring diagnostic tools meet high standards.

The level of product substitutes in the veterinary neurodegenerative disease diagnostics industry is moderate, as alternative diagnostic methods exist but often differ in accuracy, speed, and application. For example, traditional clinical neurological examinations and behavioral assessments can sometimes serve as initial diagnostic substitutes, though they lack the precision of advanced imaging like MRI or CT scans.

Companies in the veterinary neurodegenerative disease diagnostics industry are placing greater emphasis on regional expansion to take advantage of the increasing demand for advanced diagnostic solutions. Key players are focusing on emerging markets in Asia-Pacific and Latin America, motivated by factors such as the surge in pet ownership, increased veterinary healthcare expenditure, and the ongoing improvement of veterinary infrastructure in these areas. 

Product Insight

The consumables, reagents, and kits segment accounted for the largest market revenue share in 2024. These products enable veterinarians to perform advanced molecular and biochemical tests, which are critical for diagnosing complex neurodegenerative diseases that are otherwise difficult to detect through clinical symptoms alone. For example, PCR-based genetic testing kits help identify specific gene mutations responsible for inherited conditions like cerebellar atrophy in Arabian horses or degenerative myelopathy in dogs. Similarly, ELISA kits can measure levels of neuro-specific biomarkers such as neurofilament light chain or glial fibrillary acidic protein, which indicate neuronal damage or inflammation. The availability of these specialized kits allows for early diagnosis, facilitating better disease management and improving animal health outcomes.

The dominance of consumables and reagents in this market is also driven by their inherent advantages. They are typically single-use, standardized, and easy to integrate into existing veterinary lab workflows, ensuring consistency and reliability in test results. This repeatability leads to a continuous and recurring demand, fueling sustained market growth. In addition, diagnostic kits reduce the need for expensive and time-consuming procedures by providing rapid, precise, and cost-effective alternatives. Companies like IDEXX Laboratories and Zoetis have capitalized on this by developing tailored neurodegenerative diagnostic solutions that improve clinical decision-making. The convenience, speed, and accuracy provided by these consumables and kits make them invaluable tools, encouraging their widespread adoption across veterinary clinics and specialty centers globally.

Animal Type Insights

The companion segment accounted for the largest market revenue share in 2024. The segment is also anticipated to grow at the fastest CAGR over the forecast period. This growth can be attributed to factors such as the increasing adoption of pet insurance, rising pet ownership, and high prevalence of neurodegenerative diseases in companion animals. According to a March 2025 article published by PetFoodIndustry, pet ownership continues to rise in the United States, with 94 million households currently owning at least one pet, an increase from 82 million households in 2023. Dog ownership has reached 51% of households, representing approximately 68 million dogs, while cats are present in 37% of households, totaling around 49 million cats.

Moreover, conditions such as degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction syndrome are being diagnosed more frequently due to increased awareness and better diagnostic capabilities. For example, degenerative myelopathy, a progressive spinal cord disorder primarily affecting older dogs, is becoming more commonly recognized, leading to greater demand for advanced diagnostic tests like genetic screening and MRI imaging to confirm the diagnosis. Similarly, cognitive dysfunction syndrome affects aging dogs and cats, prompting pet owners and veterinarians to seek specialized treatments and monitoring tools to manage the condition.

Diagnostic Tests Insight

The imaging segment accounted for the largest market revenue share in 2024, due to its critical role in the early and accurate diagnosis of neurological disorders in animals, such as epilepsy, brain tumors, and degenerative myelopathy. Advanced imaging techniques like MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans are essential for visualizing structural and functional changes in the animal brain and spinal cord, enabling veterinarians to identify and monitor disease progression. For example, MRI is commonly used in dogs to detect brain lesions associated with canine cognitive dysfunction, a condition similar to Alzheimer’s in humans. The increasing availability of specialized veterinary imaging centers and the growing demand for precise, non-invasive diagnostic tools further contribute to the segment’s dominance in the market.

The biomarker diagnostic tests segment is anticipated to grow at the fastest CAGR over the forecast period. The tests allow early detection, monitoring, and personalized treatment of neurological diseases in animals. These tests identify specific biological indicators-such as proteins, enzymes, or genetic markers-linked to conditions like canine cognitive dysfunction or feline spongiform encephalopathy. For example, elevated levels of certain cerebrospinal fluid (CSF) proteins, such as tau or amyloid-beta, can indicate neurodegeneration in dogs, mirroring Alzheimer’s biomarkers in humans. As the demand for targeted and preventative care in companion animals rises, biomarker diagnostics offer veterinarians valuable tools for timely intervention, thereby significantly advancing the effectiveness and precision of neurodegenerative disease management.

Indication Insights

The cognitive dysfunction segment led the market with the largest revenue share of 40.35% in 2024, due to its high prevalence across both companion animals and the need for rapid, accurate detection to prevent outbreaks. For instance, according to an article published by Today's Veterinary Practice, in December 2024, Canine Cognitive Dysfunction Syndrome (CDS) in dogs and cats is frequently overlooked and underdiagnosed, despite being a common age-related neurodegenerative disorder. Research based on pet owner surveys indicates that the prevalence of CDS in dogs varies widely, ranging from approximately 22.5% to as high as 73.5%. For example, a survey targeting owners of dogs aged seven years and older found that about 75% of these dogs exhibited at least one behavioral change consistent with CDS, such as disorientation, altered interactions, sleep disturbances, or changes in activity levels.

Moreover, according to the same article, the findings from the 2024 study, which reported a 15% diagnosis rate using CDS screening questionnaires, underscore the growing recognition and diagnostic efforts for Canine Cognitive Dysfunction Syndrome (CDS) in veterinary practice. Although this rate appears lower than some owner-reported prevalence estimates, it highlights the emerging use of formal, standardized screening tools to identify neurodegenerative conditions that were previously underdiagnosed or overlooked. This increased focus on systematic screening reflects a shift toward early detection and intervention, which is crucial for managing CDS effectively.

End Use Insight

The veterinary hospitals and clinics segment accounted for the largest market revenue share in 2024, as they serve as the primary points of care where animals are first assessed and diagnosed. Unlike diagnostic laboratories that primarily focus on specialized testing, veterinary hospitals and clinics offer comprehensive, on-site diagnostic services combined with clinical evaluation, allowing for quicker decision-making and immediate treatment planning. This convenience and integrated care model encourages pet owners to seek timely veterinary attention, thereby increasing demand for neurodegenerative disease diagnostics. In addition, veterinary hospitals and clinics often invest in advanced imaging technologies such as MRI and CT scanners, enabling in-house neurodiagnostic capabilities that reduce turnaround time compared to sending samples to external labs.

The veterinary diagnostic laboratories segment is expected to grow at the fastest CAGR over the forecast period. These laboratories offer access to advanced diagnostic tools such as genetic testing, biomarker assays, and imaging analysis, which many veterinary clinics may not have the resources or equipment to perform in-house. By serving as centralized hubs for sophisticated diagnostics, they facilitate the detection and monitoring of neurodegenerative diseases like canine cognitive dysfunction, degenerative myelopathy, and cerebellar abiotrophy.

Regional Insights

North America dominated the veterinary neurodegenerative disease diagnostics market with the largest revenue share of 38.25% in 2024. This leadership position is attributed to the region’s advanced veterinary healthcare infrastructure, extensive adoption of cutting-edge technologies, high disposable income levels, and the presence of key industry players. Continued strategic initiatives by these companies are anticipated to accelerate growth within the region further. For example, global pet healthcare innovators such as Zoetis and IDEXX Laboratories, Inc., provide advanced diagnostic services, including MRI and CT scans, reinforcing their market presence.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Trends

The veterinary neurodegenerative disease diagnostics market in the U.S. is anticipated to grow at a significant CAGR over the forecast period. The country’s large pet population and increasing pet expenditure are key drivers of market growth. For example, according to the American Pet Products Association (APPA), veterinary care and routine veterinary visits generated expenditures of USD 41.4 billion in 2024. This substantial spending underscores the increasing prioritization of pet health and wellness among pet owners, which directly supports the market growth. As more owners invest in regular veterinary care, there is greater demand for advanced diagnostic services, including those for neurodegenerative conditions. Routine visits provide critical opportunities for early detection and monitoring of neurological disorders, driving the need for sophisticated diagnostic tools and technologies, thereby fueling market expansion.

Europe Veterinary Neurodegenerative Disease Diagnostics Market Trends

The veterinary neurodegenerative disease diagnostics market in Europe is poised for robust growth, fueled by factors such as the increasing prevalence of neurological diseases, rising pet ownership rates, and expanding uptake of pet insurance. The 2024 FEDIAF report highlights that approximately 50% of European households own pets, accounting for 166 million out of 352 million pets across Europe, indicating a growing customer base for veterinary services. As pets are increasingly viewed as family members, there is heightened demand for comprehensive veterinary care, including routine screenings and early disease detection. This shift drives market expansion by encouraging veterinary clinics and diagnostic laboratories to adopt and offer advanced, precise, and rapid diagnostic technologies, thereby meeting the evolving needs of pet owners and improving disease management outcomes.

The presence of leading insurance providers offering comprehensive coverage for veterinary diagnostic services significantly contributes to market growth within the country. Major players such as PetPlan, Trupanion, Nationwide, and Healthy Paws provide extensive insurance policies that encompass a broad spectrum of veterinary needs, including diagnostic testing, in-person and telehealth consultations, surgical procedures, and various treatments. By reducing the financial burden associated with advanced diagnostic services, these insurance solutions lower barriers to care, enabling pet owners to pursue timely and regular veterinary visits. This increased affordability and access drive greater adoption of advanced diagnostic technologies and tools among veterinary clinics, as insured clients are more inclined to invest in thorough diagnostic evaluations and early detection of neurodegenerative and other diseases, thereby accelerating market expansion.

Asia Pacific Veterinary Neurodegenerative Disease Diagnostics Market Trends

The veterinary neurodegenerative disease diagnostics market in Asia Pacific plays a pivotal role in driving market growth, supported by several critical factors. Rapid urbanization and rising disposable incomes have led to increased pet ownership across countries such as China, India, Japan, and Australia. For example, China has seen a substantial surge in pet adoption, with millions of new dog and cat owners emerging annually, which directly increases demand for veterinary healthcare services, including advanced diagnostics. In addition, growing awareness about pet health and wellness is encouraging owners to seek early diagnosis and treatment for neurodegenerative diseases, fueling market expansion.

The India veterinary neurodegenerative disease diagnostics market is growing at a rapid pace, driven by rising pet ownership, expanding veterinary infrastructure, and increasing demand for advanced diagnostic technologies. The country boasts over 35 million pet dogs and approximately 2.5 million pet cats as of 2024, reflecting a growing emphasis on companion animal health. This surge in pet ownership is accompanied by a cultural shift, with pets increasingly regarded as integral family members, leading to heightened demand for comprehensive veterinary care, including early detection and management of neurodegenerative diseases such as canine cognitive dysfunction and degenerative myelopathy.

Latin America Veterinary Neurodegenerative Disease Diagnostics Market Trends

The veterinary neurodegenerative disease diagnostics market in Latin America is emerging as a promising growth region, driven by rising pet ownership, increasing awareness of animal health, and expanding access to veterinary care. Countries such as Brazil and Argentina are witnessing a growing middle-class population with higher disposable incomes, which has led to a surge in pet adoption and a shift toward treating pets as family members. For instance, Brazil is among the top countries globally in terms of pet population, with over 149 million pets as of 2024, including a significant number of dogs and cats, prime candidates for neurodegenerative disease diagnostics.

The Brazil veterinary neurodegenerative disease diagnostics market is witnessing significant advancements in infrastructure and technology. The adoption of sophisticated diagnostic tools, such as molecular diagnostics and advanced imaging technologies, is enhancing the capacity for early and accurate diagnosis of neurodegenerative diseases in pets. These technological advancements are making advanced diagnostics more accessible across the country, further fueling market growth. Moreover, around 91% of Brazilian pet owners prioritize their pets' health, reflecting a growing demand for comprehensive veterinary care, including diagnostics for neurodegenerative diseases.

Middle East & Africa Veterinary Neurodegenerative Disease Diagnostics Market Trends

The veterinary neurodegenerative disease diagnostics market in the Middle East & Africa (MEA) region, comprising countries such as South Africa, Saudi Arabia, the UAE, and Kuwait, is expected to witness steady growth, driven by rising pet ownership, improving veterinary infrastructure, and growing investment in animal healthcare. In Gulf countries such as the United Arab Emirates and Saudi Arabia, pet humanization is on the rise due to lifestyle changes and increasing disposable incomes. This has led to greater demand for high-quality veterinary services, including advanced diagnostics for age-related and neurological conditions in companion animals like dogs and cats.

The South Africa veterinary neurodegenerative disease diagnostics market is playing an increasingly pivotal role in the market growth, driven by rising pet ownership, expanding veterinary infrastructure, and the adoption of advanced diagnostic technologies. Approximately 45% of South African adults are pet owners, with dogs being the most popular choice, accounting for 78% of pet-owning households. This growing pet population, coupled with the trend of treating pets as integral family members, is leading to increased demand for comprehensive veterinary care, including diagnostics for neurodegenerative conditions such as canine cognitive dysfunction and degenerative myelopathy.

Key Veterinary Neurodegenerative Disease Diagnostics Company Insights

The veterinary neurodegenerative disease diagnostics industry exhibits moderate competitiveness, marked by the presence of both established industry leaders and emerging entrants. The competitive landscape is primarily shaped by rapid technological progress and a consistent demand for innovative diagnostic solutions. To reinforce their market presence and expand their product portfolios, leading companies are increasingly engaging in strategic initiatives such as mergers and acquisitions, partnerships, and the launch of advanced diagnostic technologies. These approaches enable them to strengthen their capabilities, address shifting customer needs, and sustain a competitive advantage within an evolving market environment.

Recent Developments

• In October 2024, WOORIEN Co., Ltd, a veterinary imaging equipment and solutions specialist, introduced the 'MyVet CT Plus,' designed to accommodate various animal sizes-from small lizards to large retrievers. The MyVet CT Plus delivers significantly faster and higher-quality imaging, reducing acquisition time by at least 45% compared to its predecessor, with potential reductions of up to 80%.

• In March 2024, Animed Veterinary Group started its mobile CT service visit in Animed Veterinary Hospital and Nine Mile Veterinary Group-both members of the CVS Group Plc-once every four weeks.

• In January 2024, IDEXX Laboratories introduced the IDEXX inVue Dx Cellular Analyzer, a slide-free technology revolutionizing cytologic analysis in veterinary practices, providing rapid, consistent results with deep diagnostic insights through AI-driven imaging.

• In August 2020, IDEXX Laboratories launched a new ImageVue DR30 Digital Imaging System to enhance its digital imaging portfolio.

Veterinary Neurodegenerative Disease Diagnostics Market Report Scope

Global Veterinary Neurodegenerative Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global veterinary neurodegenerative disease diagnostics market report based on animal type, product, diagnostic tests, indication, end use, and region.

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables, Reagents & Kits

  • Equipment & Instruments

• Diagnostic Tests Outlook (Revenue, USD Million, 2018 - 2030)

  • Imaging

    • MRI (Magnetic Resonance Imaging)

    • CT (Computed Tomography)

    • Others

  • Biomarker Diagnostic Tests

    • CSF (Cerebrospinal Fluid) biomarkers

    • Blood-based biomarkers

    • Others

  • Others

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Livestock

    • Sheep

    • Cattle

    • Others

  • Companion

    • Canine

    • Feline

    • Equine

    • Others

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Cognitive Dysfunction

  • Cerebellar Abiotrophy

  • Spongiform Encephalopathies

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals and Clinics

  • Veterinary Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • India

    • China

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait